Recently, the "ICPO Theranostics FAP Summit-Targeting the Tumor Microenvironment and Beyond" was officially held in Germany. This summit aims to promote innovation in molecular precision oncology therapy in the international field and provide patients with more treatment options. Due to the impact of the COVID-19, the meeting was held in the form of live streaming. As the sponsor of the summit, multiple experts from LNC gave presentations and participated in panel discussions at the summit, including Prof. Chen Xiaoyuan, the Co-founder and Chief Scientist of LNC, and Nasrat Muzayyin Chair Professor in Medicine and Technology, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, Dr. Zhang Jingjing, Chief Medical Officer of LNC and Assistant Professor at the National University of Singapore, and Dr. Chen Haojun, Clinical Medical Advisor of LNC. In addition, Dr. Xie Zhiqian, Project Director of DC PHARMA Business Development Department, and Tong Mingyong, Project Director of Business Development Department at Andike Pharmaceutical Group, attended the meeting.

01 Global Nuclear Medicine Leaders Gather Together

This FAP summit brought together world-class nuclear medicine experts in the industry. The attending experts extensively and deeply shared the latest research achievements in the field of FAP-targeted diagnosis and treatment, and jointly discussed the development history of FAP targets, as well as the current situation and development vision.

02 The Voice of LNC at the Summit

Prof. Chen Xiaoyuan introduced the enormous potential of EB (Evans Blue) as a classic binding agent of human serum albumin in radiopharmaceutical diagnosis and precision therapy, and emphasized the outstanding performance of the innovative FAP-targeted radionuclide drug 177Lu-LNC1004 Injection developed by LNC in imaging, prolonging in vivo circulation and tumor uptake, anti-tumor efficacy, and first-in-human data.

Dr. Chen Haojun introduced that a series of research progress has been made in the tumor diagnosis and treatment with radiolabeled FAP-targeted molecular probes. He pointed out that FAPI may become another radiotheranostics precursor with broad clinical application prospects in the future, following PSMA and DOTA-TATE. As a therapeutic radiopharmaceutical, Dr. Chen Haojun highlighted new strategies that can improve tumor uptake and prolong tumor retention time, including the application of 177Lu-LNC1004 and 68Ga-FAPI-RGD in tumor diagnosis and treatment. These new research strategies are expected to enhance the effectiveness of FAPI based radionuclide therapy.

Dr. Zhang Jingjing, as one of the five invited guests at the summit, participated in the FAP Treatment Symposium Panel to explore how to improve the clinical application of FAP Therapeutics, the impact of FAP-targeted nuclear therapy on clinical management, and shared the key factors for achieving successful therapeutic effects of FAP therapy based on her clinical experience. She also emphasized the characteristics of different solid tumors in radionuclide therapy, the key therapeutic factors such as tumor uptake and sufficient tumor retention time of FAP-targeted drugs, and highlighted the clinical advantages of 177Lu-LNC1004.